These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 11576949)

  • 1. Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study).
    Oh TR; Myeong C; Song SH; Choi HS; Suh SH; Kim CS; Bae EH; Chung W; Choi KH; Oh KH; Ma SK; Kim SW
    Kidney Res Clin Pract; 2022 Mar; 41(2):200-208. PubMed ID: 34974650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.
    Demir P; Erdenen F; Aral H; Emre T; Kose S; Altunoglu E; Dolgun A; Inal BB; Turkmen A
    J Clin Lab Anal; 2016 Nov; 30(6):811-817. PubMed ID: 26991325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women.
    Lewis JR; Lim WH; Ueland T; Wong G; Zhu K; Lim EM; Bollerslev J; Prince RL
    PLoS One; 2015; 10(7):e0134266. PubMed ID: 26222774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin and kidney disease.
    Montañez-Barragán A; Gómez-Barrera I; Sanchez-Niño MD; Ucero AC; González-Espinoza L; Ortiz A
    J Nephrol; 2014 Dec; 27(6):607-17. PubMed ID: 24756971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway.
    Zhou S; Fang X; Xin H; Li W; Qiu H; Guan S
    PLoS One; 2013; 8(7):e68987. PubMed ID: 23874840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis.
    Giaginis C; Papadopouli A; Zira A; Katsargyris A; Klonaris C; Theocharis S
    Med Sci Monit; 2012 Oct; 18(10):CR597-604. PubMed ID: 23018352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin and bone mineral density in hemodialysis patients.
    Nakashima A; Yorioka N; Doi S; Takasugi N; Shigemoto K; Kohno N
    Osteoporos Int; 2006; 17(6):841-6. PubMed ID: 16604298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?
    Kananen K; Volin L; Laitinen K; Ruutu T; Välimäki MJ
    Osteoporos Int; 2006; 17(5):724-30. PubMed ID: 16437190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG].
    Sasaki N; Kusano E
    Clin Calcium; 2006 Jun; 16(6):956-62. PubMed ID: 16751691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Osteoprotegerin (OPG)].
    Takahashi N; Kimura H; Yoshida H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():818-20. PubMed ID: 16149650
    [No Abstract]   [Full Text] [Related]  

  • 11. Osteoprotegerin levels before and after renal transplantation.
    Sato T; Tominaga Y; Iwasaki Y; Kazama JJ; Shigematsu T; Inagaki H; Watanabe I; Katayama A; Haba T; Uchida K; Fukagawa M
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S175-7. PubMed ID: 11576949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients.
    Malyszko J; Malyszko JS; Wolczynski S; Mysliwiec M
    Transplant Proc; 2003 Sep; 35(6):2227-9. PubMed ID: 14529897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis.
    Sasaki N; Kusano E; Ando Y; Yano K; Tsuda E; Asano Y
    Nephrol Dial Transplant; 2001 Mar; 16(3):479-82. PubMed ID: 11239019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
    Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
    Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.